Investigation Of The Prognostic Value And Clinical Significance Of CNPY4 In Low-grade Glioma

Objective:To investigate the expression and prognostic differences of Canopy FGF Signaling Regulator 4(CNPY4)in Low-Grade Glioma(LGG),to analyze the relationship between CNPY4 and tumor immunity,and to predict the drug sensitivity of CNPY4 to temozolomide(TMZ)and cisplatin in gliomas.Methods:Expression information,prognostic information and clinical phenotypic characteristics of CNPY4 were obtained from two independent databases,The Cancer Genome Atlas(TCGA)and Chinese Glioma Genome Atlas(CGGA),as well as The Genotype-Tissue Expression(GTEx)normal tissue database,and then data were sorted and analyzed by online analysis software and R software.The differential expression of CNPY4 in glioma at the RNA level was first analyzed,and the differential expression of CNPY4 at the protein level was verified by The Human Protein Atlas(HPA)database,and then the effect of differential expression of CNPY4 on the survival of glioma was analyzed.In addition,the correlation between CNPY4 and tumor infiltrating immune cells(TIICs)was investigated by Tumor Immune Estimation Resource(TIMER)and Integrated Repository Portal for Tumor-Immune System Interactions(TISIDB),then the Tumor Immune Dysfunction and Exclusion(TIDE)algorithm was used to predict the responsiveness of CNPY4 expression towards Immune Checkpoint Blockade(ICB).And finally the possible functional pathways of CNPY4 were analyzed by Gene Set Enrichment Analysis(GSEA)and the impact of CNPY4 on glioma prognosis and drug sensitivity was analyzed by COX regression and Half-Maximal Inhibitory Concentration(IC50).Results:1.CNPY4 is highly expressed in gliomas,as a key gene in gliomas,and is associated with higher World Health Organization(WHO)classification of gliomas.2.CNPY4,as a novel molecular marker,is an independent prognostic factor of LGG,and high expression of CNPY4 suggests poor prognosis of LGG.3.CNPY4 may affect the prognosis and progression of LGG by regulating TIICs and their regulatory molecules,glioma patients with low CNPY4 expression has higher ICB responsiveness.4.High expression of CNPY4 may suggest the sensitivity of LGG patients to TMZ and cisplatin.Conclusion:1.CNPY4,a novel molecular marker,is an independent prognostic factor for LGG,and the high expression of CNPY4 suggests poor prognosis of LGG.2.CNPY4 may be a potential target for immunotherapy and may predict high sensitivity to temozolomide and cisplatin.